SW · COPN.SW
Cosmo Pharmaceuticals N.V.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Dublin 2
- Website
- cosmopharma.com
Price · as of 2024-12-31
$82.00
Market cap 1.83B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $315.90 | +285.24% |
| Intrinsic Value(DCF) | $45.41 | -44.62% |
| Graham-Dodd Method(GD) | $37.70 | -54.02% |
| Graham Formula(GF) | $1,428.50 | +1,642.07% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $18.27 | $39.64 | $9.33 | $4.90 | $6.30 |
| 2011 | $18.40 | $28.35 | $4.33 | $6.50 | $6.20 |
| 2012 | $41.53 | $52.46 | $148.88 | $13.90 | $108.60 |
| 2013 | $88.58 | $121.49 | $41.30 | $36.90 | $13.30 |
| 2014 | $156.62 | $138.90 | $247.74 | $19.90 | $227.40 |
| 2015 | $142.56 | $322.55 | $18.68 | $109.00 | $0.00 |
| 2016 | $160.63 | $255.30 | $19.38 | $14.30 | $24.70 |
| 2017 | $121.17 | $182.88 | $20.43 | $0.00 | $0.00 |
| 2018 | $78.26 | $64.55 | $22.19 | $21.90 | $0.00 |
| 2019 | $65.85 | $46.67 | $19.54 | $17.20 | $0.00 |
| 2020 | $75.74 | $227.94 | $20.36 | $23.20 | $0.00 |
| 2021 | $50.10 | $93.26 | $21.96 | $32.70 | $17.60 |
| 2022 | $53.32 | $54.33 | $42.68 | $16.20 | $61.20 |
| 2023 | $64.11 | $55.73 | $0.00 | $7.00 | $0.20 |
| 2024 | $52.29 | $337.86 | $38.70 | $37.70 | $1,428.50 |
AI valuation
Our deep-learning model estimates Cosmo Pharmaceuticals N.V.'s (COPN.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $315.90
- Current price
- $82.00
- AI upside
- +285.24%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$45.41
-44.62% upside
Graham-Dodd
$37.70
-54.02% upside
Graham Formula
$1,428.50
+1,642.07% upside
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
- CEO
- Giovanni Di Napoli
- Employees
- 321
- Beta
- 1.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($45.41 ÷ $82.00) − 1 = -44.62% (DCF, example).